Editor’s note

As policymakers strive to link budgetary allocations to better quality compliance, with stricter oversight?

With China battling another COVID wave, have previous supply shocks helped immunise India's pharma procurement systems?

The question remains, what are the plans to enforce such regulations more stringently?

Because laws are only as good as their enforcement

While formulation generics flounders a bit, the data show that the Indian API industry has done better, with a five-year revenue…

As COVID-19 continues to extract its price, will a more aware patient pool build up public opinion and turn the tide?

The regulation of all retail channels as proposed by the draft Drugs, Medical Devices and Cosmetics Bill 2022 becomes even more…

Hopefully, this case will initiate as deep a clean up and introspection as the 2012 PCC report

Will surprise site inspections be the end of a long wait? Or the start of another tunnel into noncompliance?

A policy to incentivise pharma R&D is crucial as there are already signs that pharma R&D dives when revenues dip